Beam Therapeutics [BEAM] vs Moderna [MRNA] Detailed Stock Comparison
Beam Therapeutics
NASDAQ
Loading...
Moderna
NASDAQ
Loading...
TLDR: Quick Comparison Summary
Based on 18 vital metrics comparison: Beam Therapeutics wins in 6 metrics, Moderna wins in 11 metrics, with 0 ties. Moderna appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Beam Therapeutics | Moderna | Better |
|---|---|---|---|
| P/E Ratio (TTM) | -4.56 | 24.97 | Beam Therapeutics |
| Price-to-Book Ratio | 1.95 | 1.04 | Moderna |
| Debt-to-Equity Ratio | 14.79 | 7.88 | Moderna |
| PEG Ratio | 0.46 | -2.89 | Moderna |
| EV/EBITDA | -2.49 | -1.76 | Beam Therapeutics |
| Profit Margin (TTM) | 0.00% | -94.31% | Beam Therapeutics |
| Operating Margin (TTM) | -1,419.22% | -638.73% | Moderna |
| Return on Equity | -41.94% | -27.50% | Moderna |
| Return on Assets (TTM) | -21.02% | -14.77% | Moderna |
| Free Cash Flow (TTM) | $-356.19M | $-4.06B | Beam Therapeutics |
| 1-Year Return | -24.18% | -63.64% | Beam Therapeutics |
| Price-to-Sales Ratio (TTM) | 35.05 | 3.18 | Moderna |
| Enterprise Value | $1.06B | $5.39B | Moderna |
| EV/Revenue Ratio | 17.53 | 1.75 | Moderna |
| Gross Profit Margin (TTM) | N/A | 13.14% | N/A |
| Revenue per Share (TTM) | $1 | $8 | Moderna |
| Earnings per Share (Diluted) | $-4.50 | $-7.78 | Beam Therapeutics |
| Beta (Stock Volatility) | 2.15 | 1.93 | Moderna |
Performance
News Sentiment
Key Stats
Valuation
Financials
Short Interest
Dividends
Beam Therapeutics vs Moderna Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Beam Therapeutics | -4.50% | 22.26% | 13.17% | 9.74% | -22.38% | -19.27% |
| Moderna | -1.23% | 2.65% | -4.94% | -11.76% | -30.95% | -40.88% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Beam Therapeutics | -24.18% | -64.47% | -32.29% | -3.30% | -3.30% | -3.30% |
| Moderna | -63.64% | -81.97% | -64.46% | 33.49% | 33.49% | 33.49% |
News Based Sentiment: Beam Therapeutics vs Moderna
Beam Therapeutics
News based Sentiment: MIXED
September was a mixed month for Beam Therapeutics, with positive news regarding FDA designations and clinical trial data driving a stock surge, but a revenue miss and continued insider selling creating offsetting concerns. The company's strong institutional support and upcoming investor conferences suggest continued investor interest, but careful monitoring of financial performance is warranted.
Moderna
News based Sentiment: NEGATIVE
Moderna experienced a difficult month with disappointing financial results, significant funding cuts from the HHS, and a shifting regulatory landscape. These factors combined to create a negative investment narrative, prompting analyst downgrades and a substantial decline in the company's stock price. The company is attempting to mitigate these challenges through cost-cutting measures and investor engagement, but the overall outlook remains uncertain.
Performance & Financial Health Analysis: Beam Therapeutics vs Moderna
| Metric | BEAM | MRNA |
|---|---|---|
| Market Information | ||
| Market Cap | $2.11B | $9.78B |
| Market Cap Category | Mid cap | Mid cap |
| 10 Day Avg. Volume | 2,959,170 | 11,853,956 |
| 90 Day Avg. Volume | 2,643,530 | 9,414,865 |
| Last Close | $19.94 | $24.83 |
| 52 Week Range | $13.52 - $35.25 | $23.15 - $79.96 |
| % from 52W High | -43.43% | -68.95% |
| All-Time High | $138.52 (Jun 28, 2021) | $497.49 (Aug 09, 2021) |
| % from All-Time High | -85.60% | -95.01% |
| Growth Metrics | ||
| Quarterly Revenue Growth | -0.28% | -0.41% |
| Quarterly Earnings Growth | -0.28% | -0.38% |
| Financial Health | ||
| Profit Margin (TTM) | 0.00% | -0.94% |
| Operating Margin (TTM) | -14.19% | -6.39% |
| Return on Equity (TTM) | -0.42% | -0.28% |
| Debt to Equity (MRQ) | 14.79 | 7.88 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $10.70 | $24.16 |
| Cash per Share (MRQ) | $11.71 | $13.19 |
| Operating Cash Flow (TTM) | $-344,824,000 | $-2,696,999,936 |
| Levered Free Cash Flow (TTM) | $-164,037,248 | $-2,864,375,040 |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | N/A |
| Last 12-Month Dividend | N/A | N/A |
Valuation & Enterprise Metrics Analysis: Beam Therapeutics vs Moderna
| Metric | BEAM | MRNA |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | -4.56 | 24.97 |
| Forward P/E | -4.38 | -2.89 |
| PEG Ratio | 0.46 | -2.89 |
| Price to Sales (TTM) | 35.05 | 3.18 |
| Price to Book (MRQ) | 1.95 | 1.04 |
| Market Capitalization | ||
| Market Capitalization | $2.11B | $9.78B |
| Enterprise Value | $1.06B | $5.39B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 17.53 | 1.75 |
| Enterprise to EBITDA | -2.49 | -1.76 |
| Risk & Other Metrics | ||
| Beta | 2.15 | 1.93 |
| Book Value per Share (MRQ) | $10.70 | $24.16 |
Financial Statements Comparison: Beam Therapeutics vs Moderna
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | BEAM | MRNA |
|---|---|---|
| Revenue/Sales | $7.47M | $107.00M |
| Cost of Goods Sold | N/A | $90.00M |
| Gross Profit | N/A | $17.00M |
| Research & Development | $98.82M | $856.00M |
| Operating Income (EBIT) | $-119.29M | $-1.05B |
| EBITDA | $-113.91M | $-917.00M |
| Pre-Tax Income | $-109.27M | $-964.00M |
| Income Tax | N/A | $7.00M |
| Net Income (Profit) | $-109.27M | $-971.00M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | BEAM | MRNA |
|---|---|---|
| Cash & Equivalents | $527.91M | $1.62B |
| Total Current Assets | $1.25B | $6.77B |
| Total Current Liabilities | $141.55M | $1.60B |
| Long-Term Debt | $144.92M | $702.00M |
| Total Shareholders Equity | $1.12B | $10.07B |
| Retained Earnings | $-1.68B | $9.07B |
| Property, Plant & Equipment | $176.23M | $1.25B |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | BEAM | MRNA |
|---|---|---|
| Operating Cash Flow | $-81.45M | $-691.00M |
| Capital Expenditures | $-3.07M | $-117.00M |
| Free Cash Flow | $-106.95M | $-1.16B |
| Debt Repayment | $0 | N/A |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | BEAM | MRNA |
|---|---|---|
| Shares Short | 27.17M | 62.83M |
| Short Ratio | 11.21 | 7.49 |
| Short % of Float | 0.30% | 0.22% |
| Average Daily Volume (10 Day) | 2,959,170 | 11,853,956 |
| Average Daily Volume (90 Day) | 2,643,530 | 9,414,865 |
| Shares Outstanding | 83.63M | 386.00M |
| Float Shares | 87.02M | 363.29M |
| % Held by Insiders | 0.01% | 0.07% |
| % Held by Institutions | 1.05% | 0.75% |
Dividend Analysis & Yield Comparison: Beam Therapeutics vs Moderna
| Metric | BEAM | MRNA |
|---|---|---|
| Last 12-Month Dividend | N/A | N/A |
| Last 12-Month Dividend Yield | N/A | N/A |
| 3-Year Avg Annual Dividend | N/A | N/A |
| 3-Year Avg Dividend Yield | N/A | N/A |
| 3-Year Total Dividends | N/A | N/A |
| Ex-Dividend Date | N/A | N/A |